erlotinib hydrochloride has been researched along with pioglitazone in 1 studies
Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (pioglitazone) | Trials (pioglitazone) | Recent Studies (post-2010) (pioglitazone) |
---|---|---|---|---|---|
4,353 | 786 | 3,033 | 4,338 | 824 | 2,277 |
Protein | Taxonomy | erlotinib hydrochloride (IC50) | pioglitazone (IC50) |
---|---|---|---|
CDGSH iron-sulfur domain-containing protein 1 | Rattus norvegicus (Norway rat) | 1 | |
Bile salt export pump | Rattus norvegicus (Norway rat) | 2 | |
Peroxisome proliferator-activated receptor gamma | Rattus norvegicus (Norway rat) | 0.7 | |
Bile salt export pump | Homo sapiens (human) | 0.337 | |
Carbonic anhydrase 2 | Homo sapiens (human) | 0.114 | |
Steryl-sulfatase | Homo sapiens (human) | 0.8 | |
Peroxisome proliferator-activated receptor alpha | Mus musculus (house mouse) | 1.15 | |
Amine oxidase [flavin-containing] B | Homo sapiens (human) | 0.298 | |
Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | 3.0379 | |
Peroxisome proliferator-activated receptor gamma | Mus musculus (house mouse) | 0.7 | |
CDGSH iron-sulfur domain-containing protein 2 | Homo sapiens (human) | 4.8 | |
CDGSH iron-sulfur domain-containing protein 1 | Homo sapiens (human) | 8.65 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Costa, DB; Huberman, MS | 1 |
1 other study(ies) available for erlotinib hydrochloride and pioglitazone
Article | Year |
---|---|
Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diabetes Mellitus, Type 2; Erlotinib Hydrochloride; Female; Glyburide; Humans; Lung Neoplasms; Pioglitazone; Quinazolines; Thiazolidinediones | 2006 |